All In MedTech

Company

Djo

Funding, FDA decisions, device trials, adverse event reports and recalls filed under this company's name in public data. Records are matched by name, so a subsidiary or an unusual spelling can be missed.

Last checked: Nov 19, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations

This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.

Financing

From SEC filings.

We found no SEC financing filings under the name Djo, so its financing is unknown here. That is common for companies based outside the US, for subsidiaries of larger companies, and for companies funded by founders, grants or customers. A company that changed its name can also be missed.

Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys.

Investors

5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.

No 5%+ shareholder filings or SBIR grants found under the name Djo.

Latest FDA decisions

The 8 newest of 9 since 2015.

Search the Clearance Tracker

6 more FDA decisions with a free account

Device trials

Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.

Open in the Trial Radar
  • NCT06717789 · 74 participants · Start Apr 1, 2025 · Primary completion Dec 31, 2025

    Device: Transcutaneous Electrical Nerve Stimulation (TENS) with the Compex SP8.0 device; Transcutaneous Electrical Nerve Stimulation (TENS) with the Compex SP8.0 device · For: Musculoskeletal Conditions; Musculoskeletal Pain

    Sites: Salford, United Kingdom; Worsley, United Kingdom

  • NCT06659536 · 53 participants (planned) · Start Jan 19, 2026 · Primary completion Oct 2026

    Device: Transcutaneous Tibial Nerve Stimulation (TTNS) with the Cefar Uro Device · For: Overactive Bladder (OAB); Refractory Overactive Bladder; Urinary Urgency and Frequency

    Sites: Paris, France

  • NCT06759935 · 104 participants · Start Feb 21, 2025 · Primary completion Mar 30, 2026

    Device: Sham Laser therapy; Laser therapy · For: Shoulder Pain; Shoulder Impingement Syndrome; Rotator Cuff Tendinitis

    Sites: Serris, France; Roma, Italy; Cassano d'Adda, Italy · 10 sites in all

4 more trials with a free account

Reports received

58

Received Nov 1, 2025 to Nov 19, 2026

Malfunction reports

12

21% of reports

Injury reports

46

79% of reports

Death reports

0

0.0% of reports

Adverse event reports received per month

Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.

Search the MAUDE Monitor
  • Malfunction
  • Injury
  • Death
  • Other
View as table
MonthMalfunctionInjuryDeathOther
Dec 230300
Jan 244000
Feb 244000
Mar 243000
Apr 2415400
May 2412300
Jun 248100
Jul 242200
Aug 247300
Sep 2419400
Oct 2410300
Nov 2418300
Dec 2428100
Jan 257200
Feb 2515300
Mar 2513500
Apr 2513400
May 250200
Jun 250300
Jul 255200
Aug 253600
Sep 252600
Oct 252200
Nov 251600
Dec 253600
Jan 263100
Feb 261600
Mar 261500
Apr 260800
May 262600
Jun 260100
Jul 260300
Aug 261200
Sep 260100
Oct 260100
Nov 260000

Device types named most often

Last 12 months, by FDA product code. A company that sells more gets more reports.

7 more in this ranking with a free account

Brand names named most often

Last 12 months, as written on the reports. One product can appear under several spellings.

7 more in this ranking with a free account

Recent recalls

From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.

9 more recall records with a free account

Back to all tools

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.